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045!%C'!G0%$'4%=!M$%CnM$%C2;%!5'&$,$;:!M','!J2:G0,'5!;=$41!!2, Fisher’s exact 
and Kruskal-Wallis tests where appropriate. Logistic regression analysis was used to 
calculate odds ratios and 95% confidence intervals for outcome measures associated 
with delirium. The regression model was adjusted for age, sex, race, HIV-infection, 
non-independent pre-admission activities of daily living (ADLs), the presence of a 
language barrier and ! of formal education, illness severity (MEWS) and a primary 
admission diagnosis of TB. Logistic regression analysis was used to develop the 
shortened 4-question “RACY” tool. More detailed methods are outlined in the online 
supplement. Overall performance of both the 10-question AMT and 4-question 
“RACY” was evaluated using the area under the receiver operating characteristic 
(AUROC) curve. ROC curves for 10-question AMT and 4-question “RACY” 
performance in different educational strata were compared. 10-question AMT and 4-
question “RACY” sensitivity, specificity, and positive and negative predictive values 
with 95% confidence intervals for different ROC-selected cut-points were calculated. 
STATA IC version 10 (Stata Corp, Texas, USA) was used for all statistical analyses. 
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Section and Topic Item 
# 




1 Identify the article as a study of diagnostic accuracy (recommend 
MeSH heading 'sensitivity and specificity'). 
1 
INTRODUCTION 2 State the research questions or study aims, such as estimating 
diagnostic accuracy or comparing accuracy between tests or across 
participant groups. 
6 
METHODS    
Participants 3 The study population: The inclusion and exclusion criteria, setting and 
locations where data were collected. 
7 
 4 Participant recruitment: Was recruitment based on presenting 
symptoms, results from previous tests, or the fact that the participants 
had received the index tests or the reference standard? 
7 
 5 Participant sampling: Was the study population a consecutive series of 
participants defined by the selection criteria in item 3 and 4? If not, 
specify how participants were further selected. 
7 
 6 Data collection: Was data collection planned before the index test and 
reference standard were performed (prospective study) or after 
(retrospective study)? 
7 
Test methods 7 The reference standard and its rationale. 8 
 8 Technical specifications of material and methods involved including 
how and when measurements were taken, and/or cite references for 
index tests and reference standard. 
8 
 9 Definition of and rationale for the units, cut-offs and/or categories of 
the results of the index tests and the reference standard. 
8 
 10 The number, training and expertise of the persons executing and 
reading the index tests and the reference standard. 
8 
 11 Whether or not the readers of the index tests and reference standard 
were blind (masked) to the results of the other test and describe any 
other clinical information available to the readers. 
8 
Statistical methods 12 Methods for calculating or comparing measures of diagnostic accuracy, 
and the statistical methods used to quantify uncertainty (e.g. 95% 
confidence intervals). 
9 
 13 Methods for calculating test reproducibility, if done. N/A 
RESULTS    
Participants 14 When study was performed, including beginning and end dates of 
recruitment. 
7 
 15 Clinical and demographic characteristics of the study population (at 
least information on age, gender, spectrum of presenting symptoms). 
10 
 16 The number of participants satisfying the criteria for inclusion who did 
or did not undergo the index tests and/or the reference standard; 
describe why participants failed to undergo either test (a flow diagram 
is strongly recommended). 
10/11 
Test results 17 Time-interval between the index tests and the reference standard, and 
any treatment administered in between. 
11 
 18 Distribution of severity of disease (define criteria) in those with the 
target condition; other diagnoses in participants without the target 
condition. 
12 
 19 A cross tabulation of the results of the index tests (including 
indeterminate and missing results) by the results of the reference 
standard; for continuous results, the distribution of the test results by 
the results of the reference standard. 
11,30 
 20 Any adverse events from performing the index tests or the reference 
standard. 
N/A 
Estimates 21 Estimates of diagnostic accuracy and measures of statistical 
uncertainty (e.g. 95% confidence intervals). 
30 
 22 How indeterminate results, missing data and outliers of the index tests 
were handled. 
29 
 23 Estimates of variability of diagnostic accuracy between subgroups of 
participants, readers or centers, if done. 
N/A 
 24 Estimates of test reproducibility, if done.      N/A 
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DSM-IV Criteria for Delirium 
 
 
A. Disturbance of consciousness (i.e., reduced clarity of awareness of the 

















D. There is evidence from the history, physical examination or laboratory findings 





Adapted from American Psychiatric Association: Diagnostic and Statistical Manual of 
Mental Disorders, 4th Edition, Text Revision. Washington, DC, American Psychiatric 
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our consent form, which requires the patient to have read the article. This form is available in 
multiple languages.  
• Please provide a data sharing statement such as: "Technical appendix, statistical code, and 
dataset available from the corresponding author at <email address or url>. Participants gave 
informed consent for data sharing [or ...consent was not obtained but the presented data are 
anonymised and risk of identification is low... or consent was not obtained but the potential 
benefits of sharing these data outweigh the potential harms because...]" Accession codes 
should be supplied where available. If there are no further data available, please use this 
wording: "No additional data available". During submission authors can choose to send 
supplementary or underlying data to the Dryad repository, who will provide a permanent, 
citable and open access home for the dataset.  
   
We recommend your article does not exceed 4000 words, with up to five figures and tables. Exceeding 
this will impact upon the paper's 'readability'. Supplementary and raw data can be placed online 
alongside the article, and we may request that you separate out some material into supplementary data 
files to make the main manuscript clearer for readers.  
We also recommend, but do not insist, that the discussion section is no longer than five paragraphs and 
follows this overall structure (you do not need to use these as subheadings): a statement of the principal 
findings; strengths and weaknesses of the study; strengths and weaknesses in relation to other studies, 
discussing important differences in results; the meaning of the study: possible explanations and 
implications for clinicians and policymakers; and unanswered questions and future research. 
 
Authors are encouraged to submit figures and images in colour - there are no colour charges. 
 
At upload you will be asked to choose one general subject area that applies to your article - it will be 
published under this banner on the main table of contents. You will also be asked to select further 
subject headings to be used for the 'Browse by topic' section, and specific keywords for help with 
identifying reviewers.  
Reporting guidelines 
The guidelines listed below should be followed where appropriate. Please use these guidelines to 
structure your article. Completed applicable checklists, structured abstracts and flow diagrams should 
be uploaded with your submission; these will be published alongside the final version of your paper.  
• CONSORT Statement (for reporting of randomised controlled trials: please use the 
appropriate extension to the CONSORT statement, including the extension for writing 
abstracts)  
• STARD (for reporting of diagnostic accuracy studies)  
• STROBE(for reporting of observational studies in epidemiology)  
o Checklist for cohort, case-control, and cross-sectional studies (combined) 
o Checklist for cohort studies 
o Checklist for case-control studies 
o Checklist for cross-sectional studies 
• PRISMA (for reporting of systematic reviews)  
• MOOSE (for reporting of meta-analyses of observational studies)  
• STREGA (for reporting of gene-disease association studies)  
The Equator Network (Enhancing the Quality and Transparency Of health Research) provides a 
comprehensive list of reporting guidelines.  
Data sharing 
See also our data sharing FAQs.  
Study protocols 










providing exposure to research activity that may not otherwise be widely publicised. This can help 
prevent unnecessary duplication of work and will hopefully enable collaboration. Publishing protocols 
in full also makes available more information than is currently required by trial registries and increases 
transparency, making it easier for others (editors, reviewers and readers) to see and understand any 
deviations from the protocol that occur during the conduct of the study. Various resources exist that list 
the ingredients of an authoritative trial protocol, e.g. the UK Dept of Health/Medical Research Council 
Clinical Trials Toolkit and the US National Institutes for Health provide advice on how to structure a 
trial protocol. The SPIRIT (Standard Protocol Items for Randomized Trials) statement will be available 
soon (see here for details). It is an evidence-based tool developed through systematic review of a wide 
range of resources and consensus. It closely mirrors the CONSORT statement and also reflects 
important ethics considerations. BMJ Open will consider for publication protocols for any study 
design, including observational studies and systematic reviews. We strongly encourage you to register 
your study with a registry such as www.clinicaltrials.gov (this registration is mandatory for any clinical 
trial) or Prospero for systematic reviews. General BMJ Group policies apply (see above) on manuscript 
formatting, editorial policies, licence forms and patient consent (where applicable to study designs). 
Protocols should include, as a minimum, the following items.  
• Protocol papers should report planned or ongoing studies. Articles that report results should be 
submitted as research articles.  
• Title: this should include the specific study type, e.g. randomised controlled trial.  
• Abstract: this should be structured with the following sections. Introduction; Methods and 
analysis; Ethics and dissemination. Registration details should be included as a final section, if 
appropriate.  
• Introduction: explain the rationale for the study and what evidence gap it may fill. Appropriate 
previous literature should be referenced, including relevant systematic reviews.  
• Methods and analysis: provide a full description of the study design, including the following. 
How the sample will be selected; interventions to be measured; the sample size calculation 
(drawing on previous literature) with an estimate of how many participants will be needed for 
the primary outcome to be statistically, clinically and/or politically significant; what outcomes 
will be measured, when and how; a data analysis plan.  
• Ethics and dissemination: ethical and safety considerations and any dissemination plan 
(publications, data deposition and curati n) should be covered here.  
• Full references.  
• Authors' contributions: state how each author was involved in writing the protocol.  
• Funding statement: preferably worded as follows. Either: 'This work was supported by [name 
of funder] grant number [xxx]' or 'This research received no specific grant from any funding 
agency in the public, commercial or not-for-profit sectors'.  
• Competing interests statement.  
Study 'pre-protocols' 
The journal will also be glad to consider publishing 'pre-protocols'; articles discussing provisional 
study designs that have yet to reach the stage of a formal proposal. These pre-protocols should include 
as much of the information required to publish a full protocol as possible, along with a statement of any 
areas of the study design where authors would particularly welcome comment. The pre-protocol will 
then be published online for community comment. 
 
Pre-protocols should be presented formally. They should not be 'pitches' and should not discuss 
undeveloped research questions. 
 
Pre-protocols will be peer-reviewed; reviewers will be checking that the research question and 
rationale are scientifically credible and ethically sound. They will be asked to consider the rest of the 
pre-protocol as it stands and comment on strengths and weaknesses. 
 
Based on the reviewers' comments the pre-protocol will then be accepted for publication or declined. 
There will be no revision procedure. Reviewers' comments will be published alongside the submission.  
Pilot studies 










study' applies. The term 'pilot study' should not be applied to justify reporting a small-scale study. 
Justifications for a pilot study include:  
• trialling a new procedure intended for use in a larger programme of research  
• establishing power calculations required for a full-scale study  
• establishing how many patients and/or healthcare professionals can be recruited  
• evaluating the financial, technical, administrative or logistic feasibility of a full-scale study, 
including issues of data collection, protocol adherence, and questionnaire design.  
The sample/patient size should still be justified. The article should explain the impact that the pilot 
study had on decisions regarding future research.  
Rapid responses and online comments 
We encourage readers to comment on articles published in BMJ Open. Please follow our guidelines set 
out in our Blog and eLetter response terms and requirements, available here. It is also possible to post 
less-formal comments online at the end of articles using the Disqus commenting facility.  
Peer review process  
All articles published in BMJ Open will have been sent for external, open peer review. Reviewers will 
not be asked to judge for importance or breadth of appeal. Readers will be able to make these 
judgements for themselves. We recommend you use our instructions for reviewers as a checklist to 
ensure that your article is complete. Upon publication, all previous versions of the manuscript will also 
be made available, as will the reviewers' comments and authors' replies to those comments.  
   
Peer review of study protocols 
BMJ Open will consider publishing without peer review protocols that have formal ethical approval 
and funding from a recognised, open access advocating research-funding body (as listed by the 
JULIET project). Please provide proof that these criteria are met when uploading your protocol. Any 
protocols that do not meet both these criteria will be sent for open external peer review, with reviewer 
comments published online upon acceptance, as with research articles. Reviewers will be instructed to 
review for clarity and sufficient detail. The intention of peer review is not to alter the study design. 
Reviewers will be instructed to check that the study is scientifically credible and ethically sound in its 
scope and methods, and that there is sufficient detail to instil confidence that the study will be 
conducted and analysed properly. 
 
As with research articles, protocols will be published under a Creative Commons licence.  
Supplements  
The BMJ Group journals are willing to consider publishing supplements. Supplement proposals may be 
made at the request of:  
1. The journal editor, an editorial board member or a learned society may wish to organise a 
meeting, sponsorship may be sought and the proceedings published as a supplement.  
2. The journal editor, editorial board member or learned society may wish to commission a 
supplement on a particular theme or topic. Again, sponsorship may be sought.  
3. The BMJ Group itself may have proposals for supplements where sponsorship may be 
necessary.  
4. A sponsoring organisation, often a pharmaceutical company or a charitable foundation, that 
wishes to arrange a meeting, the proceedings of which will be published as a supplement.  
In all cases, it is vital that the journal's integrity, independence and academic reputation is not 
compromised in any way. All supplements are fully peer-reviewed. For further information on criteria 
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